Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7566
- PB 5.3472
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.2431
- MktCap 278940593427.0
- FreeCF/Share 5.2238
- PFCF 21.3764
- PE 14.5662
- Debt/Assets 0.372
- DivYield 0.0296
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MRK | Wolfe Research | Peer Perform | Outperform | -- | $135 | Jan. 8, 2026 |
| Upgrade | MRK | BMO Capital Markets | Market Perform | Outperform | -- | $130 | Dec. 18, 2025 |
| Upgrade | MRK | Wells Fargo | Equal Weight | Overweight | -- | $125 | Nov. 24, 2025 |
| Initiation | MRK | Scotiabank | -- | Sector Outperform | -- | $105 | Nov. 13, 2025 |
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
News
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Published: January 09, 2026 by: WSJ
Sentiment: Positive
Revolution is developing drugs that target a molecular driver of cancers.
Read More
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Published: January 09, 2026 by: CNBC Television
Sentiment: Neutral
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Read More
Merck in Talks to Buy Revolution Medicines Per Financial Times Report
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Why Merck (MRK) is a Top Growth Stock for the Long-Term
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
The Big 3: XRT, MRK, CAT
Published: January 07, 2026 by: Schwab Network
Sentiment: Positive
@Theotrade's Don Kaufman is bullish on the SPDR E&P Retail ETF (XRT) and Caterpillar (CAT) but tilts bearish on Merck (MRK). He explains his stance on today's Big 3 and offers example options trades for each.
Read More
Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation
Published: January 07, 2026 by: Market Watch
Sentiment: Negative
Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts.
Read More
Dr. Rasha Kelej, CEO of Merck Foundation, Named One of ‘100 Most Influential Africans 2025' Alongside Presidents of Angola, South Africa, and Ghana by New African Magazine, UK
Published: January 07, 2026 by: Business Wire
Sentiment: Neutral
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #100MostInfluentialAfricans--Dr. Rasha Kelej, CEO of Merck Foundation, has been recognized as one of the 100 Most Influential Africans by New African Magazine (UK).
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Published: January 01, 2026 by: Seeking Alpha
Sentiment: Positive
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining traction: Winrevair's rapid ramp to nearly $1B, Capvaxive's $2B+ potential, and subcutaneous Keytruda QLEX extending exclusivity beyond 2028. Financial strength underpins the transition: $17.1B TTM operating cash flow, $18.2B cash, 15-year dividend growth streak, and sector-leading profitability metrics.
Read More
Merck: Framework For Success
Published: January 01, 2026 by: Seeking Alpha
Sentiment: Positive
Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, but future exclusivity loss in 2028 is a material risk. The company trades at a significant discount—13.8x forward PE, the lowest among peers—while showing the best YoY EBITDA growth and a PEG of 1.23.
Read More
Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
Published: December 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, but Animal Health growth, pipeline depth, and margin strength offer diversification and optionality. Even in conservative scenarios, MRK could deliver ~7% annualized returns, with potential for double-digit upside if new drugs succeed and margins improve.
Read More
Why Merck (MRK) is a Top Value Stock for the Long-Term
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
Read More
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans.
Read More
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Published: December 19, 2025 by: Benzinga
Sentiment: Negative
Merck & Co. Inc. (NYSE: MRK) will not exercise its option for Evaxion A/S (NASDAQ: EVAX) Gonorrhea vaccine candidate EVX-B2.
Read More
Can Merck Successfully Steer Through the Upcoming Headwinds?
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
Read More
Here's Why Merck (MRK) is a Strong Growth Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Eli Lilly or Merck: Where Should Investors Put Their Money?
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Read More
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
Read More
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Read More
Dividend Stocks for 2026: Where to Invest as the Market Cools
Published: December 10, 2025 by: MarketBeat
Sentiment: Positive
As we enter the final stretch of 2025, it's clear that this has been a strong year for equities. However, with valuations across the tech sector stretched and talk of an AI-fueled bubble growing louder, many investors are beginning to look for more stable, income-generating opportunities.
Read More
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
Read More
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
Published: December 09, 2025 by: CNBC
Sentiment: Positive
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the parasite from Mexico among multiple reasons for the decline in ranchers' livestock.
Read More
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
Read More
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert Davis
- Employees 73000